Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Health and Me on MSN
Can CRISPR cure HIV? Scientists say virus removed from cells in new research
Scientists are testing CRISPR gene editing as a potential HIV cure after successfully removing the virus from infected cells ...
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
GSK reports positive results from B-Well 1 & B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B: London, UK Thursday, January ...
DelveInsight’s “Hepatitis B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.
GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback